Pacific Edge revenue drops
Pacific Edge (cancer diagnostics) reported FY to April operating revenue of $11.5m (-47.4%) and total revenue of $13.6m (-44.7%), with net loss after tax of $35.8m. The drop followed Novitas’ denial of Medicare coverage for Cxbladder tests in the US. Pacific Edge raised $36.1m from existing investors and says a draft Medicare determination could restore coverage for Triage/Triage Plus, with Triage Plus priced at $US1328.
How this was made
The 30-second read
Why it matters
The newest concrete facts are the FY revenue decline figures and the publication of a draft Medicare determination proposing coverage for Triage and Triage Plus, which the company frames as a path to renewed growth and profitability.
Market read
Traders should focus on the Medicare reimbursement catalyst for Triage/Triage Plus and how it may reverse the revenue/margin damage from the prior Cxbladder non-coverage decision.
What to watch
The article notes potential narrower coverage for Triage (vs prior legacy tests) and relies on switching to Triage Plus for margin; actual uptake and final policy scope could differ from expectations.
Background
Pacific Edge is a cancer diagnostics company whose US reimbursement for Cxbladder tests was halted after Novitas denied Medicare coverage; it later pursued reconsideration for Triage products.
Ticker impact
Pacific Edge reports FY revenue nearly halved after Novitas denied Medicare coverage for its Cxbladder tests, cutting reimbursement.
Near-term sentiment likely remains pressured until a final Medicare determination; upside skew if coverage is confirmed and broader switching to Triage Plus occurs.
The article ties the revenue decline directly to Novitas’ Medicare non-coverage and highlights a draft determination proposing coverage again, implying a binary regulatory catalyst for future cash flows.
Market effects
US reimbursement policy for bladder-cancer diagnostics is a key swing factor for revenue visibility and valuation multiples in the diagnostics space.
Asia-Pacific private payer mitigation is cited, suggesting regional payer mix can partially offset US Medicare shocks.
US Medicare coverage decisions can rapidly change demand and margins for cross-border diagnostic providers.
Counterpoint
Even with draft coverage proposals, the company’s large net loss and prior reimbursement halt suggest execution and payer adoption risk may delay profitability despite potential coverage.
Key entities
- companyPacific Edge
Reports FY revenue nearly halved due to Medicare coverage being halted for Cxbladder; expects growth acceleration if Triage/Triage Plus coverage is finalized.
- regulator/administratorNovitas
Medicare jurisdiction for Pacific Edge’s US laboratory; denied Medicare coverage for Cxbladder tests, ending reimbursement.
- guideline bodyAmerican Urological Association (AUA)
Included Cxbladder Triage in microhematuria guidelines, supporting Pacific Edge’s reconsideration request.
